Industrial Production of Recombinant Proteins: Challenges and Innovations

The recombinant protein is relevant in the field of biotechnology, and they serve into therapy, diagnostics, and industrial processes. They become synthesised when they are made within host organisms, e.g. bacteria, yeast or mammalian cells, with target genes introduced into them. However, realistic concerns about high-efficient and scalable production of recombinant proteins have become characteristic as the recombinant proteins poorly express, are non-soluble, and fail to fold at all. Moreover, the recombinant proteins are non-capable of various post-translational modification and are too costly to make an ideal production. In this paper, these challenges are examined and access some of the innovations in beating them, including synthetic biology, CRISPR gene editing, and improved cell culture tools. A lot has already been achieved but currently more technology is needed so that the recombinant proteins can meet the rising demand. The article pays special attention to the importance of a multidisciplinary aspect on which genetic engineering, bioprocess optimization, and bio products have to be combined. It will also be the case that artificial intelligence and machine learning advancements will mean optimized monitoring, scale-up and yield forecast of a bio-process so that biopharmaceuticals can be provided with high quality recombinant proteins at economical costs.